HKeyBio has launched its NHP Fast-Tox Program, which accelerates early toxicology screenings for drug candidates, enhancing safety assessments significantly.

HKeyBio has unveiled the pioneering HKEY-NHP-onChip™ 1.1, the first non-human primate model for autoimmune and allergic diseases, boosting research efficiency.

HkeyBio has launched a comprehensive disease model platform focused on autoimmune diseases, enhancing drug R&D through innovative translational research strategies.

Discover how AI is transforming drug discovery for autoimmune diseases, creating new opportunities for specialized preclinical research organizations.

HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration...

Discover how HKeyBio's innovative HKEY-AI2Vivo™ 1.0 program accelerates in vivo validation of AI-generated drug candidates in autoimmune and allergy research.

HKeyBio has launched the HKEY-AI4AI-Atlas™ 1.0, an innovative AI-assisted platform for standardizing autoimmune model datasets for research.

HKeyBio introduces the HKEY-AI-NAM-Bridge™ 1.0, a groundbreaking service that merges AI with preclinical drug development methodologies to foster innovation.

HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI-NAM-Bridge™ 1.0, its AI and New Approach Methodologies (NAMs)...

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies. The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics across various tissues […]

HKeyBio has launched HKEY-ExE™ 1.0, a framework designed to tackle preclinical challenges in drug development for eosinophilic conditions, enhancing efficiency and outcomes.

HkeyBio unveils its innovative NHP Fast-PoC program, offering low-cost pharmacological validation data to help biotech companies navigate drug development challenges.

In a strategic shift, HKEYBIO has announced significant price reductions on autoimmune model services despite a global shortage of Non-Human Primates, supporting biopharma innovation.

HKeybio Tech has introduced the first-ever NHP model for Hidradenitis Suppurativa, addressing the challenges in drug development for this chronic condition.

HKeyBio introduces HKEY-AIRx™1.0, a novel preclinical strategy aimed at enhancing the success of asthma and allergy drug programs by addressing core challenges in biotech development.

HKeyBio has launched the HKEY-NHP-MATRIX2.0, a cutting-edge platform designed to enhance the translation of autoimmune and allergic disease treatments from research to clinical settings.

The EoE-centered framework supports disease modeling, multidimensional efficacy endpoints, type 2 biomarker analysis, and cross-indication translational research BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical contract research organization focused on...

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on...

The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO...

BOSTON and SUZHOU, China, June 3, 2026 /PRNewswire/ -- HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates standardized rodent models with...

HkeyBio Builds a High-Efficiency Wet-Lab Validation Engine with Comprehensive CRO Service Upgrades in 2026 BOSTON and SUZHOU, China, May 26, 2026 /PRNewswire/ -- I. Industry Background: AI-Driven Drug Discovery Fuels Explosive Demand for Wet-Lab Validation, Creating New Opportunities for...

The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO...

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection...

BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch of HKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel...